FindTrial
Sign In

Sirolimus (RAPAMUNE)

DRUG5 trials

Sponsors

Wyeth is now a wholly owned subsidiary of Pfizer, St. Joseph's Healthcare Hamilton, West China Hospital, Central Adelaide Local Health Network Incorporated

Conditions

Graft vs Host DiseaseHaemodialysis PatientsKidney TransplantationLiver TransplantationLymphatic MalformationOlder AdultsProstate CancerVaccine Immune Response

Phase 2

Effectiveness of Conversion to Sirolimus Versus Calcineurin Inhibitor (CNI) Reduction in Renal Transplant Patients With Prostate Cancer
WithdrawnNCT00922129
St. Joseph's Healthcare HamiltonProstate Cancer
Start: 2009-09-30End: 2011-01-31Updated: 2014-01-14
Different Doses of Sirolimus for the Treatment of Cystic Lymphatic Malformations
RecruitingNCT06673290
West China HospitalLymphatic Malformation
Start: 2024-11-30End: 2026-12-30Target: 150Updated: 2024-12-31
Vaccination Response Modulation With a Targeted Rapamycin Protocol Study
Not yet recruitingNCT07587801
Central Adelaide Local Health Network IncorporatedHaemodialysis Patients, Older Adults, Vaccine Immune Response
Start: 2026-05-01End: 2026-07-01Target: 60Updated: 2026-05-14

Phase 3

Study Evaluating Sirolimus (Rapamune™) in Solid Organ Transplant Recipients
CompletedNCT00037531
Wyeth is now a wholly owned subsidiary of PfizerGraft vs Host Disease, Kidney Transplantation
End: 2004-08-31Updated: 2009-08-18
Study Evaluating of Calcineurin Inhibitor and Sirolimus (Rapamune) Treatment in Liver Transplant Recipients
TerminatedNCT00086346
Wyeth is now a wholly owned subsidiary of PfizerLiver Transplantation
Start: 2002-12-31End: 2008-07-31Updated: 2010-04-28